Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 study of perampanel oral suspension as adjunctive therapy in pediatric epilepsy (4 to <12 years)
jRCT2080223425Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2016
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of perampanel in Focal Onset Epilepsy, sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability of adjunctive perampanel and Exposure–efficacy relationship. Started Dec 2016; status: completed.
02
Drugs
perampanel
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on jRCT2080223425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223425.